The October issue of Biotecnika Magazine focuses on the healthcare faction, highlighting people who have been made famous, even infamous, through their contributions to the machinations that directly or indirectly changed the course of human well-being. From hospital borne diseases that are leaving patients sicker than when they arrived (“Are our hospitals making patients sicker?”) to decoding DNA in outer space (“Kate Rubbins in Outer Space”), these stories talk about the pitfalls and triumphs of the bioscience field in medicine. Our focus stories are on three current problems: the Bayer Monsanto merger, the hideous inflation of prices for the life-saving Epipen, the argument for and against using gene drive technology and how scientists can protect (or be divested of) their findings through the manipulation of IPR protocols. We have had the honour of interviewing Dr Arun Garg, the head of the department of Neurology at Medanta Medicity and Dr Sanjiv Agarwal, the founder of Diabetacare and profusely thank them for taking time of their busy schedules to answer our questions.
About BioTecNika Magazine:
Biotecnika Info Labs Pvt Ltd, (established in 2006) located in Bangalore, Noida, Kolkata & Pune (India), is a bio-science information portal lead by a group of biotechnologists, efforting tominimize the extant gap between industry and the personnel associated with bio-science.
Biotecnika Magazine, founded in the year 2013, is one of the India’s largest growing magazine which serves as an essential guide to a plethora of audience fromindustry and academia. Distinguished by its in-depth analysis and latest information, magazine showcases its features that are insightful, informative and presented with style. The list does not stop as we also bring to you the country’s first web TV broadcasting various events, interviews and programs to interest our readers.
Biotecnika magazine being interpreted as a “Mirror to Biotechnology Industry”, delivers the best of bioscience world to its audience from every vertical. Constantly striving to be the leading life science magazine in the country, we yearn to be an insight into the bioscience sector and uphold “Business to Business” and “Business to Consumer” relationship.
Currently with a response involving more than 9,25,000 (Online), the ardor to serve you better has only amplified.